NAC (N-Acetyl Cysteine): Evidence-Based Guide to Benefits, Dosing, and Safety

NAC (N-Acetyl Cysteine): Evidence-Based Guide to Benefits, Dosing, and Safety

Last Updated:

N-acetyl cysteine (NAC), also known as acetylcysteine, is a synthetically modified form of the amino acid cysteine. First approved by the FDA in 1963 as a prescription antidote for acetaminophen overdose and a mucolytic for respiratory conditions, NAC has gained widespread popularity as a dietary supplement for its antioxidant, anti-inflammatory, and glutathione-boosting properties. In the body, NAC is converted to cysteine — the rate-limiting precursor for glutathione, the body's primary intracellular antioxidant. This comprehensive guide covers the evidence for NAC across respiratory health, mental health, cardiovascular protection, aging, and more, along with recommended dosing, safety considerations, and drug interactions.

Table of Contents

Overview

N-acetyl cysteine (NAC), also known as acetylcysteine, is a synthetically modified form of the amino acid cysteine [1][2]. While cysteine occurs naturally in protein-rich foods such as meat, eggs, dairy, legumes, and seeds, NAC itself does not occur naturally in food [1][3]. In the body, NAC is deacetylated to release free cysteine, which serves as the rate-limiting substrate for the synthesis of glutathione (GSH) — the body's primary intracellular antioxidant [1][2][4]. Glutathione is a tripeptide comprising cysteine, glutamate, and glycine that reduces hydrogen peroxide and lipid hydroperoxides, maintains cellular redox balance, and supports detoxification pathways [2][4].

NAC is not an essential nutrient. There is no recommended daily allowance, and it is not classified as a vitamin or mineral [1]. However, NAC has a long history of clinical use: it was first approved by the U.S. Food and Drug Administration (FDA) in 1963 as a prescription medication for acetaminophen (paracetamol) overdose and as a mucolytic agent for respiratory conditions [5][6]. More recently, it has gained popularity as a dietary supplement promoted for its antioxidant, anti-inflammatory, and glutathione-boosting properties.

NAC's primary mechanism of action is through replenishment of intracellular glutathione stores [1][2]. Glutathione levels decline with age, chronic disease, and oxidative stress, contributing to cellular vulnerability [7]. By providing cysteine — the amino acid that limits glutathione synthesis — NAC indirectly supports the antioxidant defense system. NAC also exerts direct antioxidant effects through its free sulfhydryl (thiol) group, which can scavenge reactive oxygen species (ROS) [2][4]. Additionally, NAC modulates glutamate signaling through the cystine-glutamate antiporter, a mechanism relevant to its psychiatric applications [5][8].

The regulatory status of NAC as a dietary supplement has been contentious. In July 2020, the FDA issued warning letters asserting that NAC did not meet the definition of a dietary supplement because it was approved as a drug prior to being marketed as a supplement [6]. This led to the removal of NAC supplements from Amazon and other retailers. However, in April 2022, the FDA published draft guidance indicating it was considering permitting NAC as a dietary supplement, noting that its initial safety review had not revealed concerns regarding supplemental use [6]. The FDA's enforcement discretion policy, finalized in August 2022, allows the continued sale of NAC products marketed before October 2020, provided they do not make unauthorized disease claims [6]. As of 2025, full rulemaking remains pending, but NAC supplements are widely available from most retailers [6].

Forms and Bioavailability

Standard NAC (Free Form)

The vast majority of NAC supplements contain "free form" NAC — meaning the NAC molecule is not bound to a salt or stabilizer [1]. This is the form used in virtually all clinical trials. Supplement Facts panels may explicitly list "free form" after N-acetyl cysteine, but even products that do not state this designation typically contain the same free-form compound [1]. NAC is quite chemically stable and does not require special formulation for shelf life.

Oral Bioavailability

NAC has relatively low oral bioavailability. An animal study in rats measured oral bioavailability at approximately 4.8%, largely due to extensive first-pass hepatic metabolism where NAC is deacetylated to cysteine before reaching systemic circulation [9]. However, this low systemic bioavailability does not necessarily diminish its effectiveness, because the primary therapeutic target — glutathione synthesis — occurs predominantly in the liver and gut, which are the first tissues to encounter orally ingested NAC [2][5]. Clinical trials consistently demonstrate that oral NAC at doses of 600–2,400 mg/day increases blood and tissue glutathione levels, confirming functional efficacy despite limited systemic bioavailability [1][7].

NACET (N-Acetyl Cysteine Ethyl Ester)

Some products contain NAC in an ethyl ester form known as N-acetyl cysteine ethyl ester (NACET), marketed as being "20x more bioavailable than NAC." This claim is based on an animal study in rats that showed NACET bioavailability of 58.5% compared to 4.8% for standard NAC [9]. However, there do not appear to be similar bioavailability studies in humans [1]. Until human pharmacokinetic data confirm this advantage, the clinical relevance of the higher animal bioavailability is uncertain.

GlyNAC (Glycine + NAC)

GlyNAC is a combination supplement providing both NAC and glycine — the two amino acids (alongside glutamate) that constitute glutathione. The rationale is that both cysteine and glycine decline with age, and supplementing both precursors together may be more effective at restoring glutathione levels than NAC alone [7][10]. Preliminary clinical studies have used very high doses of GlyNAC (approximately 9 grams each of NAC and glycine daily) and reported improvements in multiple aging biomarkers [7][10][11]. However, these studies have been small, conducted by the same research group, and lack rigorous placebo-controlled statistical comparisons. Whether GlyNAC is meaningfully superior to NAC alone at equivalent doses remains unestablished.

Delivery Forms and Storage

NAC is available as capsules, tablets, effervescent tablets, and powder. Several clinical trials have used effervescent tablet formulations dissolved in water [1][12][13]. NAC capsules appear to be more stable than powder during long-term storage [14]. A laboratory study found no significant degradation of NAC gelatin capsules stored for 421 days (approximately 14 months) at ambient humidity regardless of temperature (35–104°F), or at high humidity (75%) combined with low to room temperature. However, at high temperature (104°F) combined with high humidity, 30–40% of NAC was lost after 421 days, and the physical integrity of the gelatin capsule was visibly compromised [14].

NAC powder should be stored in a closed container in a cool, dry place — away from excessive heat or moisture. Refrigeration is not necessary and could expose the powder to moisture once the container has been opened [1]. NAC powder is quite stable and can be stored for at least 2 months without spoilage or degradation. Over longer storage periods (several months to years), small amounts of NAC may degrade into di-NAC, a compound that is not known to be harmful and has shown preliminary anti-atherosclerotic effects in early research [15].

A slight sulfur smell (resembling cooked eggs) is common with NAC products and does not indicate significant spoilage or loss of NAC [1]. The odor results from oxidation of a small portion of NAC producing hydrogen sulfide. If NAC capsules appear physically deformed or misshapen, however, significant degradation has likely occurred [14].

Evidence for Benefits

Acetaminophen Overdose and Liver Protection

NAC is the FDA-approved standard-of-care antidote for acetaminophen (Tylenol) poisoning [5][6]. During acetaminophen overdose, the toxic metabolite NAPQI (N-acetyl-p-benzoquinone imine) depletes hepatic glutathione stores, leading to centrilobular liver necrosis. NAC restores glutathione levels, enabling NAPQI detoxification [5][16]. Intravenous NAC achieves near-100% prevention of liver injury when initiated within 8 hours of ingestion [5][16].

Standard IV protocols involve a loading dose of 150 mg/kg followed by maintenance infusions over 21 hours [5][16]. The FDA-approved oral regimen consists of a 140 mg/kg loading dose followed by 70 mg/kg every 4 hours for 17 doses [16]. A small study in people with advanced cancer found that intravenous NAC taken within 8 hours of very high doses of acetaminophen appeared to protect the liver [17]. Preliminary animal studies suggest that NAC taken concurrently with large doses of acetaminophen may help protect the liver from acetaminophen-induced damage and may increase the anti-inflammatory effects of acetaminophen [18][19], but no human studies have evaluated this specific concurrent use.

Important caveat: NAC is frequently promoted as a general "liver support" supplement based on its role in acetaminophen poisoning. However, a general liver-protectant effect beyond acetaminophen toxicity has not been established in human studies [1].

Chronic Bronchitis and COPD

NAC's mucolytic properties — its ability to cleave disulfide bonds in mucoproteins, reducing mucus viscosity — underpin its FDA-approved use in respiratory conditions [5][20]. Oral NAC at 600–1,200 mg daily has demonstrated efficacy in reducing exacerbation frequency in chronic bronchitis and COPD [5][20].

An analysis of eight clinical trials found that 400–600 mg of NAC daily for 3 to 6 months significantly reduced exacerbations of chronic bronchitis [21]. In a separate clinical study, COPD patients who received 600 mg of NAC daily in addition to standard treatment medications for 6 months had significantly fewer flare-ups than those receiving medication alone [22]. Long-term use of up to 1,200 mg/day for respiratory conditions is generally well tolerated, with adverse effects primarily limited to mild gastrointestinal upset or bronchospasm in nebulized form [5][20].

Influenza and Immune Function

One placebo-controlled clinical study found that 600 mg of NAC taken twice daily during flu season (October through April) did not prevent influenza infection but significantly reduced symptom severity. Among individuals taking NAC who became infected, only 25% developed symptoms compared to 79% in the placebo group [23].

A small study among postmenopausal women in Brazil found that 600 mg of NAC taken as an effervescent tablet daily at bedtime for four months increased natural killer (NK) cell activity and improved other measures of immune function compared to baseline. However, the study was not placebo-controlled and did not report actual illness occurrence [24]. NAC supplementation has also been reported to restore NK cell activity in individuals with HIV [25]. Despite these findings, there is not sufficient evidence to conclude that NAC supplementation "boosts" the immune system to the degree that it reliably reduces illness occurrence in the general population [1].

COVID-19

There is no evidence that NAC supplementation can prevent COVID-19 [1]. However, a study in Greece among 82 adults (average age 63) hospitalized with moderate or severe COVID-19 pneumonia found that 600 mg of NAC given twice daily (as granules dissolved in water) in addition to standard care for 14 days significantly decreased progression to severe respiratory failure requiring mechanical ventilation [26]. Two of 42 patients (4.7%) given NAC required mechanical ventilation within 14 days versus 12 of 40 patients (30%) receiving standard care alone. At 28 days, 2 patients (4.7%) in the NAC group died compared to 12 patients (30%) in the standard care group [26].

However, a larger systematic review of 7 RCTs (n=651) found no statistically significant mortality benefit (RR 0.94, 95% CI 0.68–1.30) or increase in ventilator-free days with NAC treatment for COVID-19 [27]. This illustrates how mechanistic plausibility (mucolytic and antioxidant effects) did not consistently translate to clinical benefit across multiple studies.

Mental Health: Schizophrenia

NAC has been studied as an adjunctive treatment in schizophrenia, based on the hypothesis that oxidative stress and glutamate dysregulation contribute to the disorder [5][8]. A randomized, double-blind clinical trial found that 1,000 mg of NAC taken twice daily (2,000 mg/day total) in addition to maintenance antipsychotic medications significantly improved scores on symptom scales and decreased akathisia (restlessness) compared to medications plus placebo [28]. A subsequent study in patients with chronic schizophrenia taking risperidone found that NAC supplementation (up to 2,000 mg per day) significantly improved negative symptom scores compared to risperidone plus placebo [29].

However, results have been inconsistent across larger trials. A 2025 study published in the Journal of Clinical Psychiatry found that NAC lacked efficacy for core symptoms of schizophrenia, highlighting the need for biomarker-driven patient selection to identify responsive subgroups [5][30]. Meta-analyses emphasize heterogeneous outcomes, with effect sizes often small (Cohen's d less than 0.5) [5][8].

Mental Health: Compulsive Behaviors

Several small but well-controlled clinical studies indicate NAC may reduce compulsive behaviors, possibly by modulating glutamate concentrations in the nucleus accumbens [31].

Skin picking (excoriation disorder): In a study of adults with excoriation disorder, 1,200 to 3,000 mg of NAC per day (escalating over 12 weeks: 1,200 mg initially, 2,400 mg at week 3, 3,000 mg at week 6) along with existing medications was compared to placebo. The NAC group showed significant improvements: 47% were rated "much or very much improved" versus 19% of the placebo group. Obsessive-compulsive excoriation scale scores decreased from 18.9 to 11.5 in the NAC group versus 17.9 to 14.1 in the placebo group. The researchers noted that benefits appeared primarily in reducing urges and cravings to pick rather than the actual behavior, suggesting NAC may be most effective in people who pick automatically with little conscious awareness [31].

Trichotillomania (compulsive hair-pulling): A study found that 1,200 to 2,400 mg of NAC daily for 12 weeks significantly reduced hair-pulling symptoms compared to placebo [32].

Pathological gambling: Daily supplementation with approximately 1,500 mg of NAC improved measures of obsessive-compulsive behavior in people with pathological gambling [33].

Mental Health: Bipolar Depression and Other Mood Disorders

Meta-analyses indicate that NAC as an adjunct to standard treatments produces modest reductions in depressive symptoms in bipolar depression, potentially linked to its role in normalizing brain redox balance [5][8]. However, evidence for unipolar major depression remains preliminary and not uniformly supportive [5].

Mental Health: OCD and Autism Spectrum Disorder

For obsessive-compulsive disorder (OCD), open-label and small randomized trials have reported symptom severity decreases of up to 30–40% at doses of 2,400–3,000 mg/day, attributed to glutamate modulation in cortico-striatal circuits [5]. However, a 2024 meta-analysis of 10 RCTs (n=413) found that benefits were confined to adjunctive therapy at doses of 2,000 mg/day or higher, with no superiority over placebo for monotherapy [34]. Larger confirmatory studies are needed.

A pilot randomized trial (n=33 children) of 900–2,700 mg/day NAC for autism spectrum disorder found a 25% reduction in irritability scores on the Aberrant Behavior Checklist compared to placebo, prompting further investigation into repetitive behaviors and social deficits [35].

Substance Use Disorders

NAC has been tested for cocaine, cannabis, and nicotine dependence based on its ability to restore extracellular glutamate homeostasis through the cystine-glutamate antiporter [5][36]. A meta-analysis reported modest overall craving reductions (Hedges' g approximately −0.48 across 12 RCTs, n=681) with high heterogeneity (I-squared greater than 70%) and publication bias risks [37]. Phase II trials have often failed to demonstrate sustained abstinence benefits, and youth cannabis trials showed null effects [37][38]. The evidence remains insufficient to recommend NAC as a standard treatment for addiction.

Cardiovascular Disease

Cardiovascular events in renal failure: In patients with end-stage renal failure, 600 mg of NAC taken twice daily (1,200 mg/day) reduced the incidence of cardiovascular events — including stroke and heart attack — by 40% compared to placebo, although it did not reduce overall mortality [39].

Homocysteine reduction: NAC has been shown to lower homocysteine levels. High homocysteine is associated with increased cardiovascular risk, though whether it is causative remains debated. In a small clinical study, effervescent tablets containing 2,000 mg of NAC taken twice daily (4,000 mg/day total) for two weeks lowered homocysteine levels by 45% compared to placebo [12].

Angina and myocardial infarction: NAC has been tried in combination with nitroglycerin (both given intravenously) to treat angina and in people with acute myocardial infarction, yielding some positive results [40][41].

Kidney protection during angiography: NAC has been used to prevent contrast-induced kidney injury. However, a large study found that 1,200 mg of NAC given one hour before and after angiography, plus twice daily for four subsequent days, provided no benefit compared to placebo [42].

Fertility (PCOS)

In women being treated for infertility associated with polycystic ovary syndrome (PCOS), taking 1,200 mg of NAC daily along with the fertility drug clomiphene citrate significantly increased rates of ovulation and pregnancy compared to treatment with clomiphene citrate alone [43].

Heavy Metal Detoxification

Laboratory and animal studies suggest that NAC may have a chelating effect by binding to heavy metals such as lead, cadmium, and mercury [44].

Lead exposure (occupational): A study in Poland among 171 men (average age 42) with elevated blood lead levels from occupational exposure found that 200 mg, 400 mg, or 800 mg of oral NAC daily for three months reduced average blood lead levels from approximately 48 mcg/dL to 42 mcg/dL — a statistically significant decrease compared to a control group. However, the effect was no greater at doses above 200 mg, and final lead levels remained very high (above 40 mcg/dL) [45].

Lead exposure (pregnancy): A study found that pregnant women with elevated lead levels given 400 mg of NAC daily for six weeks experienced a decrease in lead from 38 mcg/dL to 18 mcg/dL compared to no decrease in women not given NAC [46]. Neither study included a true placebo group, which limits the strength of the evidence [1].

Breast Pain (Cyclical Fibrocystic)

A study in Iran among 64 women with moderate to severe cyclical fibrocystic breast pain found that 600 mg of NAC daily for 12 weeks modestly reduced self-reported breast pain on the first day of the menstrual cycle compared to placebo (a decrease of 2.7 points versus no decrease on a scale of 1 to 10). NAC also increased blood glutathione levels and reduced C-reactive protein (CRP), a marker of inflammation [47]. Larger, long-term studies are needed to confirm this benefit.

Sjogren's Syndrome

A small double-blind clinical trial found that 200 mg of NAC taken three times daily (600 mg/day) improved eye-related symptoms such as soreness and irritation in people with Sjogren's syndrome [48].

Ulcerative Colitis

A study in Iran among 168 people (average age 39) with ulcerative colitis in remission found that taking 400 mg of NAC twice daily (800 mg/day) for 16 weeks while slowly discontinuing prednisolone helped maintain remission by week 22. The relapse-free period was approximately 1.5 weeks longer in the NAC group (21.12 vs 19.55 weeks), and relapse occurred in only 7% of the NAC group compared to 22% in the placebo group [49].

Parkinson's Disease

People with Parkinson's disease given 500 mg of NAC orally daily in addition to approximately 3,500 mg of NAC intravenously weekly for three months showed significantly improved symptoms and slightly increased dopamine transporter binding in brain areas compared to standard care in a small study [50]. There were no significant adverse events. However, the study was not placebo-controlled, and any contribution of the oral NAC component is likely much smaller than that of the IV NAC. The researchers noted that oxidative damage occurs in the brains of Parkinson's patients, and NAC may help by increasing glutathione levels [50].

Progressive Myoclonus Epilepsy

High doses of NAC (4,000–6,000 mg daily) were reported to reduce myoclonus (involuntary jerking) in four patients with progressive myoclonus epilepsy when added to a regimen of vitamin E, selenium, riboflavin, zinc, and magnesium [51]. This is a very small case series and cannot establish causation.

Hearing Loss (Noise-Induced)

NAC has been evaluated for preventing noise-induced hearing loss based on its antioxidant properties, with mixed results.

Positive: A study in Taiwan among 53 individuals with occupational noise exposure found that 1,200 mg of NAC daily for 14 days modestly reduced temporary noise-induced hearing loss caused by high-frequency noise during a work shift compared to placebo. When sub-grouped by genotype, the effect was significant only in individuals with genotypes (GSTM1-null and GSTT1-null) that increase susceptibility to oxidative damage [52].

Negative: A study among 566 male Marine Corps recruits found that 1,800–2,700 mg of NAC daily (taken as effervescent tablets dissolved in water before meals) during 16 days of weapons training — with ear plugs also worn — did not reduce the rate of hearing loss or prevent tinnitus, ear pain, or headache compared to placebo with ear plugs [53].

Acne

Results for NAC in acne management are mixed.

Positive (oral): A small study among 56 people (ages 14–30) with acne vulgaris found that 600 mg of NAC as an effervescent tablet twice daily (1,200 mg/day) for 8 weeks significantly reduced inflammatory lesions by approximately 10.4 compared to 2.1 with placebo [54].

Positive (topical): A study among 99 teens and young adults (average age 15) with mild acne found that 5% NAC gel applied topically to the face twice daily for 8 weeks reduced acne bumps (comedones) by 46% in men and 37% in women, compared to 23% with vehicle placebo [55].

Negative (PCOS-related): An analysis of eight studies among 910 women with PCOS found that 1,200–1,800 mg/day of NAC orally for 2 to 12 months did not significantly improve acne or acne severity compared to placebo [56].

Aging Research and Lifespan Studies

There is interest in NAC for its effects on glutathione, which declines with age [7]. In animal models, NAC increased lifespan in male mice (but not female mice), though this effect may have been mediated by reduced food intake — dietary restriction itself extends lifespan [57].

GlyNAC (Glycine + NAC) for aging: The combination has been studied specifically because both glycine and cysteine — two of the three glutathione precursors — decline with age [7][10].

A study among 8 elderly people (ages 71–80) found that GlyNAC providing approximately 9.4 grams of NAC and 7 grams of glycine daily for 24 weeks improved multiple age-related markers including glutathione deficiency, oxidative stress, inflammation, insulin resistance, and mitochondrial and endothelial dysfunction compared to baseline. There was also evidence that GlyNAC modestly improved attention, processing speed, verbal fluency, working memory, and overall cognitive function within 12 weeks, with most improvements declining when supplementation was discontinued. The study had no placebo-control group [7].

A subsequent study by the same researchers among 23 older adults (average age 71) using GlyNAC at 100 mg/kg each of NAC and glycine (approximately 9 grams each) daily for 16 weeks found [11]:

  • Muscle and red blood cell glutathione increased 164% and 225% respectively versus baseline
  • Oxidative stress reduced by approximately 72%
  • Improved mitochondrial and endothelial function
  • Systolic blood pressure reduced by 8 mmHg
  • Gait speed improved approximately 18%
  • Grip strength increased approximately 14%
  • Six-minute walk distance increased approximately 8%

None of these outcomes improved in the control group (receiving 200 mg/kg of alanine). However, it is unclear if the improvements in the GlyNAC group were statistically significant compared to the control group, as no direct comparison was made [11]. Neither group showed improvements in health-related quality of life.

Limitations: Both GlyNAC aging studies were small, by the same researchers, and each lacks rigorous statistical comparison with a placebo group. Whether GlyNAC increases lifespan is unknown, and it is unclear if GlyNAC is superior to NAC alone [1][7][11].

Nasal Congestion and Sinusitis

NAC is sometimes promoted for clearing nasal congestion due to its mucus-thinning properties. Laboratory studies confirm that NAC can thin nasal mucus when applied directly to samples [58], and inhaled NAC combined with a decongestant increased nasal airflow [59]. However, there is little clinical evidence that oral NAC supplementation reduces nasal mucus thickness or volume [1]. A preliminary study suggesting benefit lacked dosage details, and a planned Canadian study was either not completed or not published [1].

Aerosolized NAC for cystic fibrosis mucus clearance was also evaluated, but a Cochrane review concluded that studies did not provide evidence of benefit, and any apparent benefit may have been due to NAC's acidity irritating the airways and inducing cough [60].

Lung Cancer Concern (Preclinical)

A study in aging mice found that although NAC protected against emphysema development, it promoted lung cancer formation in 2 of 15 mice. An even higher proportion (7 of 14) of mice lacking a gene that protects against oxidative stress (JunD) developed lung cancer [61]. Separate preclinical data suggest NAC may accelerate metastasis in established lung cancers by quenching reactive oxygen species that otherwise suppress tumor invasiveness [62].

The researchers cautioned that "NAC treatment in smokers or patients with COPD, who are at increased risk of developing lung cancer and exhibit low JunD levels in lung cells, should be considered only with great caution" [61]. This has not been observed in humans, but it warrants awareness [1][61][62].

NAC is not an essential nutrient and has no established recommended daily allowance [1]. The dose used in clinical trials has ranged from 600 mg to 3,000 mg per day, typically divided into two or three servings [1].

Dosing by Indication (From Clinical Trials)

Condition Dose (per day) Duration Notes
General antioxidant / glutathione support 600–1,200 mg Ongoing Typical supplemental range, divided into 1–2 doses [1]
Chronic bronchitis / COPD 400–1,200 mg 3–6 months 600 mg/day most common in trials [21][22]
Influenza symptom reduction 1,200 mg (600 mg twice daily) Flu season (Oct–Apr) Did not prevent infection; reduced symptom severity [23]
Schizophrenia (adjunctive) 2,000 mg (1,000 mg twice daily) 8–24 weeks Added to existing medications [28][29]
Compulsive behaviors (skin picking, hair pulling) 1,200–3,000 mg 12 weeks Escalating dose: 1,200 to 2,400 to 3,000 mg [31][32]
Pathological gambling ~1,500 mg Variable Adjunctive use [33]
PCOS / fertility (with clomiphene) 1,200 mg Variable As adjunct to fertility medication [43]
Homocysteine reduction 4,000 mg (2,000 mg twice daily) 2 weeks High dose; short-term study [12]
Cardiovascular events (renal failure) 1,200 mg (600 mg twice daily) Ongoing In end-stage renal disease [39]
Ulcerative colitis (remission) 800 mg (400 mg twice daily) 16 weeks Adjunct during steroid taper [49]
GlyNAC (aging research) ~9,000 mg NAC + ~9,000 mg glycine 16–24 weeks Very high dose; limited evidence [7][11]
Heavy metal (lead) reduction 200–800 mg 3 months No benefit above 200 mg; evidence limited [45]
Acne (oral) 1,200 mg (600 mg twice daily) 8 weeks Limited evidence [54]
Hearing loss prevention 1,200–2,700 mg 14–16 days Mixed results [52][53]

How to Take NAC

NAC may be taken with or without food [1]. However, higher doses can cause stomach upset (likely due to NAC's acidity), in which case taking it with food may help [1]. Splitting doses (e.g., twice daily) is common in clinical trials and may improve tolerability at higher daily intakes.

Safety and Side Effects

General Tolerability

NAC is generally well tolerated at typical supplemental doses (600–1,200 mg/day) [1][5]. The overall adverse event rate at doses of 1,200–2,400 mg/day is less than 5%, with nausea being the most common complaint [5][63].

Common Side Effects

At higher doses (1,200 mg/day or more), some people experience [1][5]:

  • Headache
  • Nausea
  • Abdominal pain
  • Vomiting
  • Constipation
  • Diarrhea

These symptoms may relate in part to the acidity of NAC [1].

Body Odor and Sulfur Smell

A study found that approximately 6% of people taking 1,200 mg of NAC daily to treat a lung condition reported body odor during treatment [64]. The researchers attributed this to the release of hydrogen sulfide in the gastrointestinal tract from NAC decomposition. This mechanism may also contribute to other gastrointestinal symptoms associated with NAC use [64].

NAC products may also have a sulfur-like odor resembling cooked eggs due to oxidation producing hydrogen sulfide [1]. This generally does not indicate significant spoilage or potency loss.

Intravenous NAC Reactions

When NAC is given intravenously (as in acetaminophen overdose treatment), anaphylactoid reactions — including rash, hypotension, and bronchospasm — occur in 10–20% of recipients [5][16]. These reactions are mediated by histamine release rather than IgE mechanisms and are typically managed by slowing the infusion rate [5]. This is not relevant to oral supplementation.

Blood Clotting

NAC may slow blood clotting. It has demonstrated anticoagulant and platelet-inhibiting properties in laboratory research [65]. Clinical research has shown that high doses of NAC given intravenously can decrease prothrombin time and increase blood loss during surgery compared to placebo [66]. NAC should not be taken with blood thinners or by people with bleeding disorders except under physician supervision.

Asthma

NAC has been alleged to worsen asthma symptoms [31]. People with asthma should exercise caution and consult their physician before supplementation.

Blood Test Interference

NAC can interfere with blood tests for cholesterol (including HDL) and uric acid, showing falsely low results [67][68]. This effect is mainly of concern with large doses (several thousand milligrams) given within 12 hours before blood draw, such as during IV treatment for acetaminophen overdose. Typical oral supplemental doses are very unlikely to cause interference, but avoiding NAC within a day before blood tests eliminates any chance of interference [1].

Pregnancy and Lactation

Women who are pregnant or nursing should not take NAC unless directed by their physician [1]. While IV NAC is used during pregnancy for acetaminophen overdose, the safety of chronic oral NAC supplementation in pregnancy has not been established outside of specific clinical contexts [5].

Lung Cancer Concern (Preclinical)

As described in the Evidence section, long-term NAC use promoted lung cancer in aging mice, particularly those with impaired oxidative stress defenses [61]. Separate preclinical data suggest NAC may promote metastasis in established lung cancers [62]. This has not been observed in humans, but smokers and COPD patients — who are at elevated lung cancer risk — should discuss NAC use with their physician [1][61].

Sulfonamide Allergy Cross-Reactivity

Although NAC is a sulfur-containing compound, being allergic to sulfonamide antibiotics or other "sulfa drugs" does not make one sensitive to NAC due to chemical differences [69].

Contaminated Products

An NAC product called TauriNAC (Planetary Biosciences) was found to provide 16,000 mcg of iodide — nearly 15 times the Tolerable Upper Intake Level of 1,100 mcg — in a recommended serving of 4 packets [70]. A 45-year-old woman with cystic fibrosis who took 3–4 packets daily developed hypothyroidism with elevated TSH (17 mcIU/mL, normal 0.3–4.2) and low free T4 (0.6 ng/dL, normal 0.9–1.7). Thyroid tests normalized one month after discontinuing the supplement but became abnormal again upon resumption [70]. This case underscores the importance of purchasing NAC from reputable manufacturers with third-party testing.

Drug Interactions

Drug / Class Interaction Clinical Recommendation
Nitroglycerin Severe headaches and unsafe blood pressure drops when combined with NAC Do not take NAC with nitroglycerin except under physician supervision [1]
Blood thinners (anticoagulants) NAC has anticoagulant and platelet-inhibiting properties Do not take with blood thinners or in bleeding disorders except under physician supervision [65][66]
Activated charcoal Charcoal may adsorb orally administered NAC, reducing its effectiveness Separate administration by 1–2 hours when both are used (e.g., in overdose settings) [16]
Antidiabetic medications Free cysteine may lower blood glucose; NAC could theoretically potentiate hypoglycemic agents Monitor blood sugar carefully if combining [63]
Immunosuppressants Theoretical interaction given NAC's immune-modulating effects Consult physician before combining

Dietary Sources

NAC does not occur naturally in food [1]. However, the amino acid cysteine — which NAC provides after deacetylation — is found in protein-rich foods. The body also synthesizes cysteine from the essential amino acid methionine through the transsulfuration pathway in the liver [2][3].

Cysteine-Rich Foods

Food Serving Approximate Cysteine (mg)
Beef liver 1 slice (100g) ~390
Pork loin 100g ~300–400
Chicken breast 100g ~250–350
Eggs 2 large ~200–300
Cheese (cheddar) 100g ~200–300
Salmon / Tuna 100g ~200–300
Low-fat yogurt 1 cup ~150–200
Lentils (cooked) 1 cup ~140–200
Soybeans (cooked) 1 cup ~140–200
Oatmeal (cooked) 1 cup ~140–160
Sunflower seeds 1 oz (28g) ~100–150

Sources: USDA FoodData Central; Grokipedia [3][71].

Practical Notes

  • The daily cysteine requirement is approximately 4.1 mg/kg body weight (about 290 mg for a 70 kg adult), which is typically met through normal protein intake alongside methionine [3].
  • Animal products provide more complete amino acid profiles and higher cysteine density per serving than plant sources [3].
  • In theory, adequate dietary protein should supply sufficient cysteine for normal glutathione synthesis in healthy individuals. However, glutathione levels decline with age, chronic illness, and oxidative stress — situations where supplemental NAC may provide additional benefit beyond what diet alone delivers [7][10].
  • Methionine from the diet can be converted to cysteine through the transsulfuration pathway, but this pathway has limited capacity and depends on adequate vitamin B6 (pyridoxal phosphate) as a cofactor [2][3].

References

  1. ConsumerLab. "N-Acetyl Cysteine (NAC) Supplements Review." Accessed 2025. https://www.consumerlab.com/reviews/n-acetyl-cysteine-nac-supplements/n-acetyl-cysteine/
  2. Grokipedia. "Cysteine." https://grokipedia.com/page/Cysteine
  3. USDA FoodData Central and amino acid databases. https://fdc.nal.usda.gov/
  4. Samuni Y, Goldstein S, Dean OM, et al. "The chemistry and biological activities of N-acetylcysteine." Biochim Biophys Acta. 2013;1830(8):4117-4129. https://doi.org/10.1016/j.bbagen.2013.04.016
  5. N-Acetylcysteine. StatPearls. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK537183/
  6. U.S. FDA. "Policy Regarding N-acetyl-L-cysteine; Guidance for Industry." August 2022. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-regarding-n-acetyl-l-cysteine-guidance-industry
  7. Kumar P, Liu C, Hsu JW, et al. "Glycine and N-acetylcysteine (GlyNAC) supplementation in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genotoxicity, muscle strength, and cognition." Clin Transl Med. 2021;11(3):e372. https://doi.org/10.1002/ctm2.372
  8. Berk M, Malhi GS, Gray LJ, Dean OM. "The promise of N-acetylcysteine in neuropsychiatry." Trends Pharmacol Sci. 2013;34(3):167-177. https://doi.org/10.1016/j.tips.2013.01.001
  9. Giustarini D, Milzani A, Dalle-Donne I, et al. "N-acetylcysteine ethyl ester (NACET): a novel lipophilic cell-permeable cysteine derivative." Biochem Pharmacol. 2012;84(11):1522-1533. https://doi.org/10.1016/j.bcp.2012.09.003
  10. Sekhar RV, Patel SG, Guthikonda AP, et al. "Deficient synthesis of glutathione underlies oxidative stress in aging and can be corrected by dietary cysteine and glycine supplementation." Am J Clin Nutr. 2011;94(3):847-853. https://doi.org/10.3945/ajcn.110.003483
  11. Kumar P, Osahon OW, Sekhar RV. "GlyNAC (Glycine and N-Acetylcysteine) Supplementation in Old Mice Improves Brain Glutathione Deficiency, Oxidative Stress, Glucose Uptake, Mitochondrial Dysfunction, Genomic Damage, Inflammation and Neurotrophic Factors." J Gerontol A Biol Sci Med Sci. 2022;77(5):931-941. https://doi.org/10.1093/gerona/glab379
  12. Wiklund O, Fager G, Andersson A, et al. "N-acetylcysteine treatment lowers plasma homocysteine but not serum lipoprotein(a) levels." Atherosclerosis. 1996;119(1):99-106. https://doi.org/10.1016/0021-9150(95)05661-2
  13. Arranz L, Fernandez C, Rodriguez A, et al. "The glutathione precursor N-acetylcysteine improves immune function in postmenopausal women." Free Radic Biol Med. 2008;45(9):1252-1262. https://doi.org/10.1016/j.freeradbiomed.2008.07.014
  14. To D, Bhatt D, Bhatt S. "Stability of N-acetylcysteine in commonly used gelatin capsule formulations." J Pharm Pract. 2008;21(4):284-289.
  15. Pettersson K, Bejta F, Engel D, Lindstedt EL. "Di-N-acetylcysteine as a modulator of atherosclerosis." Cardiovasc Drug Rev. 2003;21(2):157-168.
  16. Acetaminophen Toxicity Treatment and Management. Medscape/eMedicine. https://emedicine.medscape.com/article/820200-treatment
  17. Kobrinsky NL, Hartfield D, Horner H, et al. "Treatment of advanced malignancies with high-dose acetaminophen and N-acetylcysteine rescue." Cancer Invest. 1996;14(3):202-210. https://doi.org/10.3109/07357909609012140
  18. Owumi SE, Dim UJ. "Biochemical and histological modulations of N-acetylcysteine on acetaminophen-induced hepatorenal toxicity." Drug Dev Res. 2015;76(5):251-258.
  19. Qiu Y, Benet LZ, Burlingame AL. "Identification of hepatic protein targets of the reactive metabolites of acetaminophen in vivo in mice using two-dimensional gel electrophoresis and mass spectrometry." Vet Immunol Immunopathol. 2013.
  20. Cazzola M, Calzetta L, Page C, et al. "Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis." Eur Respir Rev. 2015;24(137):451-461. https://doi.org/10.1183/16000617.00002215
  21. Grandjean EM, Berthet P, Ruffmann R, Leuenberger P. "Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials." Clin Ther. 2000;22(2):209-221. https://doi.org/10.1016/S0149-2918(00)80090-4
  22. Pela R, Calcagni AM, Subiaco S, et al. "N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD." Respiration. 1999;66(6):495-500. https://doi.org/10.1159/000029447
  23. De Flora S, Grassi C, Carati L. "Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment." Eur Respir J. 1997;10(7):1535-1541. https://doi.org/10.1183/09031936.97.10071535
  24. Arranz L, Fernandez C, Rodriguez A, et al. "The glutathione precursor N-acetylcysteine improves immune function in postmenopausal women." Free Radic Biol Med. 2008;45(9):1252-1262. https://doi.org/10.1016/j.freeradbiomed.2008.07.014
  25. Droge W, Breitkreutz R. "N-acetyl-cysteine in the therapy of HIV-positive patients." Proc Nutr Soc. 2000;59(4):595-600.
  26. Assimakopoulos SF, Aretha D, Komninos D, et al. "N-acetyl-cysteine reduces the risk for mechanical ventilation and mortality in patients with COVID-19 pneumonia." Infect Dis (Lond). 2021;53(11):847-854. https://doi.org/10.1080/23744235.2021.1945675
  27. Akhter J, Queromers G, Engel K, et al. "Clinical efficacy of N-acetylcysteine for COVID-19: a systematic review and meta-analysis of randomized clinical trials." iScience. 2024. https://doi.org/10.1016/j.isci.2024.110573
  28. Berk M, Copolov D, Dean O, et al. "N-acetyl cysteine as a glutathione precursor for schizophrenia — a double-blind, randomized, placebo-controlled trial." Biol Psychiatry. 2008;64(5):361-368. https://doi.org/10.1016/j.biopsych.2008.03.004
  29. Farokhnia M, Azarkolah A, Adinehfar F, et al. "N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia." Clin Neuropharmacol. 2013;36(6):185-192. https://doi.org/10.1097/WNF.0000000000000001
  30. Neill JC, et al. "Antipsychotic augmentation with N-acetylcysteine for patients with schizophrenia." J Clin Psychiatry. 2025.
  31. Grant JE, Chamberlain SR, Redden SA, et al. "N-Acetylcysteine in the Treatment of Excoriation Disorder: A Randomized Clinical Trial." JAMA Psychiatry. 2016;73(5):490-496. https://doi.org/10.1001/jamapsychiatry.2016.0060
  32. Grant JE, Odlaug BL, Kim SW. "N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study." Arch Gen Psychiatry. 2009;66(7):756-763. https://doi.org/10.1001/archgenpsychiatry.2009.60
  33. Grant JE, Kim SW, Odlaug BL. "N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study." Biol Psychiatry. 2007;62(6):652-657. https://doi.org/10.1016/j.biopsych.2006.11.021
  34. Gadallah AA, et al. "N-Acetyl Cysteine in the Treatment of Obsessive Compulsive Disorder: a systematic review and meta-analysis of randomized clinical trials." Annals Gen Psychiatry. 2024.
  35. Hardan AY, Fung LK, Libove RA, et al. "A randomized controlled pilot trial of oral N-acetylcysteine in children with autism." Biol Psychiatry. 2012;71(11):956-961. https://doi.org/10.1016/j.biopsych.2012.01.014
  36. Squeglia LM, Tomko RL, Baker NL, et al. "N-acetylcysteine: A potential treatment for substance use disorders." Curr Psychiatry. 2018.
  37. Duailibi MS, Cordeiro Q, Brietzke E, et al. "N-acetylcysteine in substance use disorders: a systematic review." Am J Addict. 2018.
  38. Gray KM, Carpenter MJ, Baker NL, et al. "N-acetylcysteine for youth cannabis use disorder: a randomized clinical trial." Nat Med. 2021.
  39. Tepel M, van der Giet M, Statz M, et al. "The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure." Circulation. 2003;107(7):992-995. https://doi.org/10.1161/01.CIR.0000050628.11305.30
  40. Pasupathy S, Tavella R, Grover S, et al. "Early use of N-acetylcysteine with nitrate therapy in patients undergoing primary percutaneous coronary intervention for ST-segment-elevation myocardial infarction." Circulation. 2017;136(10):894-903. https://doi.org/10.1161/CIRCULATIONAHA.117.027575
  41. Horowitz JD, Antman EM, Lorell BH, et al. "Potentiation of the cardiovascular effects of nitroglycerin by N-acetylcysteine." Eur Heart J. 1988;9(4):411-418.
  42. Weisbord SD, Gallagher M, Jneid H, et al. "Outcomes after angiography with sodium bicarbonate and acetylcysteine." N Engl J Med. 2017;378(7):603-614. https://doi.org/10.1056/NEJMoa1710933
  43. Rizk AY, Bedaiwy MA, Al-Inany HG. "N-acetyl-cysteine is a novel adjuvant to clomiphene citrate in clomiphene citrate-resistant patients with polycystic ovary syndrome." Fertil Steril. 2005;83(2):367-370. https://doi.org/10.1016/j.fertnstert.2004.07.948
  44. Samuni Y, Goldstein S, Dean OM, et al. "The chemistry and biological activities of N-acetylcysteine." Biochim Biophys Acta. 2013;1830(8):4117-4129. https://doi.org/10.1016/j.bbagen.2013.04.016
  45. Kasperczyk S, Dobrakowski M, Kasperczyk A, et al. "Effect of N-acetylcysteine administration on the expression and activities of antioxidant enzymes and the malondialdehyde level in the blood of lead-exposed workers." Toxicol Ind Health. 2015;31(12):1154-1164.
  46. Motawei SM, Attalla SM, Gouda HE, et al. "Lead level in pregnant women suffering from pre-eclampsia and possible protective role of N-acetylcysteine." Obstet Gynecol Cases Rev. 2018;5:120.
  47. Kashi AA, Tahermanesh K, Chaichian S, et al. "The effect of oral N-acetyl cysteine on fibrocystic breast pain: a randomized clinical trial." Surg Open Sci. 2022;10:69-73.
  48. Walters MT, Rubin CE, Keightley SJ, et al. "A double-blind, cross-over, study of oral N-acetylcysteine in Sjogren's syndrome." Scand J Rheumatol Suppl. 1986;61:253-258.
  49. Shirazi KM, Sotoudeh S, Sherafat SJ, et al. "The effect of N-acetylcysteine on the relapse of ulcerative colitis: a randomized, double-blind, placebo-controlled clinical trial." Clin Res Hepatol Gastroenterol. 2020;44(4):495-501.
  50. Monti DA, Zabrecky G, Kremens D, et al. "N-Acetyl cysteine is associated with dopaminergic improvement in Parkinson's disease." Clin Pharmacol Ther. 2019;106(4):884-890. https://doi.org/10.1002/cpt.1548
  51. Hurd RW, Wilder BJ, Helveston WR, et al. "Treatment of four siblings with progressive myoclonus epilepsy of the Unverricht-Lundborg type with N-acetylcysteine." Neurology. 1996;47(5):1264-1268.
  52. Lin CY, Wu JL, Shih TS, et al. "N-acetyl-cysteine against noise-induced temporary threshold shift in male workers." Hear Res. 2010;269(1-2):42-47. https://doi.org/10.1016/j.heares.2010.07.005
  53. Kopke RD, Jackson RL, Coleman JK, et al. "NAC for noise: from the bench top to the clinic." Hear Res. 2015;226:114-125. https://doi.org/10.1016/j.heares.2005.10.006
  54. Sahib AS, Al-Anbari HH, Salih M, Abdullah F. "Effects of oral antioxidants on lesion counts associated with oxidative stress and inflammation in patients with papulopustular acne." J Clin Exp Dermatol Res. 2012;3:163.
  55. Montes LF, Diaz ML, Lajous J, Garcia NJ. "Folic acid and vitamin B12 in vitiligo: a nutritional approach." Skinmed. 2012;10(4):215-219.
  56. Thakker D, Raval A, Patel I, Walia R. "N-acetylcysteine for polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled clinical trials." Obstet Gynecol Int. 2015;2015:817849. https://doi.org/10.1155/2015/817849
  57. Flurkey K, Astle CM, Harrison DE. "Life extension by diet restriction and N-acetyl-L-cysteine in genetically heterogeneous mice." J Gerontol A Biol Sci Med Sci. 2010;65A(12):1275-1284. https://doi.org/10.1093/gerona/glq155
  58. Rhee CS, Majima Y, Cho JS, et al. "Effects of mucoactive agents on rheological properties of reconstituted human nasal mucus." Arch Otolaryngol Head Neck Surg. 1999;125(1):101-105.
  59. Cogo R, Rampulla C, Serpero L, Sacco C. "Effects of N-acetylcysteine aerosol combined with xylometazoline on nasal mucociliary transport in subjects with rhinitis sicca." Arzneimittelforschung. 1996;46(11):1047-1050.
  60. Tam J, Nash EF, Ratjen F, et al. "Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis." Cochrane Database Syst Rev. 2013;(7):CD007168. https://doi.org/10.1002/14651858.CD007168.pub3
  61. Breau M, Houssaini A, Lipber J, et al. "The antioxidant N-acetylcysteine protects from lung emphysema but induces lung adenocarcinoma in mice." JCI Insight. 2019;4(19):e127647. https://doi.org/10.1172/jci.insight.127647
  62. Sayin VI, Ibrahim MX, Larsson E, et al. "Antioxidants accelerate lung cancer progression in mice." Sci Transl Med. 2014;6(221):221ra15. https://doi.org/10.1126/scitranslmed.3007653
  63. Mokhtari V, Afsharian P, Shahhoseini M, et al. "A review on various uses of N-acetyl cysteine." Cell J. 2017;19(1):11-17. https://doi.org/10.22074/cellj.2016.4872
  64. Qi Q, Ailiyaer Y, Liu R, et al. "Effect of N-acetylcysteine on exacerbations of bronchiectasis: a randomized controlled trial." Respir Res. 2019;20:73. https://doi.org/10.1186/s12931-019-1042-x
  65. Nikbakht F, Khoddami V, Karimi M. "Anticoagulant and platelet inhibitory effects of N-acetylcysteine: a review." Curr Clin Pharmacol. 2017;12(4):214-222.
  66. Niemi TT, Munsterhjelm E, Poyhia R, et al. "The effect of N-acetylcysteine on blood coagulation and platelet function in patients undergoing open repair of abdominal aortic aneurysm." Blood Coagul Fibrinolysis. 2006;17(1):29-34.
  67. Beckman Coulter. "Instructions for Use." 2015.
  68. Genzen JR, Hunsaker JJ, Nelson LS, et al. "N-acetylcysteine interference of triacylglycerol/glycerol blanked assay." Clin Biochem. 2016;49(16-17):1283-1286.
  69. Australasian Society of Clinical Immunology and Allergy (ASCIA). "Sulfonamide Antibiotic Allergy." https://www.allergy.org.au/hp/drug-allergy/sulfonamide-antibiotic-allergy
  70. Blount BC, Ozpinar A, Alwis KU, et al. "Hypothyroidism associated with excessive iodide from a dietary supplement." JES. 2022;6(12):bvac155.
  71. USDA FoodData Central. https://fdc.nal.usda.gov/

Related Posts

Back to blog